General Information |
| Clinical trials phase |
Phase 2 |
| Start date (estimated) |
2023-12-01 |
| End date (estimated) |
2024-11-30 |
| Clinical feature |
| Label |
Graft versus host disease |
| Link |
http://www.orpha.net/ORDO/Orphanet_39812 |
| Description |
A rare disease that occurs after allogeneic hematopoietic stem cell transplant and is a reaction of donor immune cells against host tissues. Activated donor T cells damage host epithelial cells after an inflammatory cascade that begins with the preparative regimen. |
|
Administrative Information |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2300077942 |
| Other study identifiers |
| Name |
ChiCTR2300077942 |
| Description |
Chinese Clinical Trial Registry (ChiCTR) |
|
| Source weblink |
https://www.chictr.org.cn/showproj.html?proj=201633 |
| Sponsors |
West China Hospital of Sichuan University
|
Cells |
Recruitment |
| Recruitment Status |
Recruiting |
| Estimated number of participants |
18 |
